Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus
NCT ID: NCT03920267
Last Updated: 2025-04-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
261 participants
INTERVENTIONAL
2019-03-26
2025-03-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
NCT03252587
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
NCT04857034
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
NCT06875960
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
NCT05620407
An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis
NCT03943147
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BMS-986165 Dose 1
BMS-986165
Specified dose on specified days
BMS-986165 Dose 2
BMS-986165
Specified dose on specified days
BMS-986165 Dose 3
BMS-986165
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-986165
Specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Evidence of active tuberculosis (TB)
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 0077
Birmingham, Alabama, United States
Local Institution - 0030
El Cajon, California, United States
Local Institution - 0049
Torrance, California, United States
Local Institution - 0074
New Haven, Connecticut, United States
Local Institution - 0115
Aventura, Florida, United States
Local Institution - 0044
Brandon, Florida, United States
Local Institution - 0140
Gainesville, Florida, United States
Local Institution - 0133
Orlando, Florida, United States
Local Institution - 0032
Ormond Beach, Florida, United States
Local Institution - 0048
Tampa, Florida, United States
Local Institution - 0094
Atlanta, Georgia, United States
Local Institution - 0050
Lawrenceville, Georgia, United States
Local Institution - 0123
Brooklyn, New York, United States
Local Institution - 0131
New York, New York, United States
Local Institution - 0071
Chapel Hill, North Carolina, United States
Local Institution - 0031
Charlotte, North Carolina, United States
Local Institution - 0064
Oklahoma City, Oklahoma, United States
Local Institution - 0035
Wyomissing, Pennsylvania, United States
Local Institution - 0121
Charleston, South Carolina, United States
Local Institution - 0001
Jackson, Tennessee, United States
Local Institution - 0041
Austin, Texas, United States
Tekton Research - Austin
Austin, Texas, United States
Local Institution - 0114
Dallas, Texas, United States
Local Institution - 0037
Houston, Texas, United States
Local Institution - 0046
Mesquite, Texas, United States
Clinica Adventista Belgrano
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Local Institution - 0125
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Local Institution - 0098
Rosario, Santa Fe Province, Argentina
Local Institution - 0091
San Miguel de Tucum, Tucumán Province, Argentina
Local Institution - 0100
CABA, , Argentina
Local Institution - 0122
Córdoba, , Argentina
Local Institution - 0095
Mendoza, , Argentina
Local Institution - 0116
Salvador, Estado de Bahia, Brazil
Local Institution - 0118
Goiߡ, Goiás, Brazil
Local Institution - 0106
Juiz de Fora, Minas Gerais, Brazil
Local Institution - 0120
Curitiba, Paraná, Brazil
Local Institution - 0107
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution - 0111
São Bernardo do Campo, São Paulo, Brazil
Local Institution - 0105
São Paulo, , Brazil
University of Calgary
Calgary, Alberta, Canada
Local Institution - 0136
Toronto, Ontario, Canada
Local Institution - 0108
Barranquilla, , Colombia
Local Institution - 0101
Bogotá, , Colombia
Local Institution - 0103
Chía, , Colombia
Local Institution - 0096
Zipaquirá, , Colombia
Local Institution - 0039
Debrecen, , Hungary
Local Institution - 0038
Gyula, , Hungary
Local Institution - 0045
Szeged, , Hungary
National Hospital Organization Chibahigashi National Hospital
Chiba, Chiba, Japan
Local Institution - 0092
Kitakyushu, Fukuoka, Japan
Local Institution - 0119
Sapporo, Hokkaido, Japan
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
Local Institution - 0063
Sendai, Miyagi, Japan
Local Institution - 0069
Shimotsuke, Tochigi, Japan
Local Institution - 0065
Chuo-ku, Tokyo, Japan
Local Institution - 0078
Tokyo, , Japan
Local Institution - 0066
Tokyo, , Japan
Local Institution - 0093
Tokyo, , Japan
Local Institution - 0080
León, Guanajuato, Mexico
Local Institution - 0086
León, Guanajuato, Mexico
Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.
Zapopan, Jalisco, Mexico
Local Institution - 0087
Mexico City, Mexico City, Mexico
Local Institution - 0084
Monterrey, Nuevo León, Mexico
Local Institution - 0082
San Luis Potosí City, , Mexico
Local Institution - 0025
Bydgoszcz, , Poland
Local Institution - 0015
Kościan, , Poland
Local Institution - 0014
Krakow, , Poland
Local Institution - 0027
Krakow, , Poland
Local Institution - 0018
Krakow, , Poland
Local Institution - 0016
Lublin, , Poland
Local Institution - 0024
Poznan, , Poland
Local Institution - 0029
Sosnowiec, , Poland
Local Institution - 0019
Warsaw, , Poland
Local Institution - 0022
Warsaw, , Poland
Local Institution - 0010
Wroclaw, , Poland
Local Institution - 0023
Wroclaw, , Poland
Local Institution - 0033
Brasov, , Romania
Local Institution - 0004
Galati, , Romania
Local Institution - 0002
Râmnicu Vâlcea, , Romania
Local Institution - 0056
Kemerovo, , Russia
Local Institution - 0072
Novosibirsk, , Russia
Local Institution - 0057
Orenburg, , Russia
Local Institution - 0062
Saint Petersburg, , Russia
Local Institution - 0058
Saint Petersburg, , Russia
Local Institution - 0070
Smolensk, , Russia
Local Institution - 0055
Vladimir, , Russia
Local Institution - 0068
Yaroslavl, , Russia
Local Institution - 0060
Yaroslavl, , Russia
Local Institution - 0061
Yekaterinburg, , Russia
Local Institution
Seoul, , South Korea
Local Institution - 0053
Suwon, , South Korea
Local Institution - 0126
Málaga, , Spain
Local Institution - 0138
Sabadell, , Spain
Local Institution - 0124
Seville, , Spain
Local Institution - 0052
Taichung, , Taiwan
Local Institution - 0051
Taipei, , Taiwan
Local Institution
Taipei, , Taiwan
Local Institution - 0137
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-003471-35
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
IM011-074
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.